Blarcamesine works better when taken earlier in Alzheimer's: Study
Blarcamesine appeared to slow the decline of cognition and functional capacity for people with Alzheimer’s disease in a long-term trial.| Alzheimer's News Today
Blarcamesine appeared to slow the decline of cognition and functional capacity for people with Alzheimer’s disease in a long-term trial.| Alzheimer's News Today
A new dosing regimen for Kisunla, to help lower the risk of certain side effects, has been approved by the U.S. Food and Drug Administration.| Alzheimer's News Today
After a third review of safety data, an independent board recommended two trials of simufilam for Alzheimer's continue without modification.| Alzheimer's News Today
Alzamend Neuro is partnering with Mass General Hospital for a Phase 2 trial of AL001, a next-generation lithium drug for Alzheimer’s dementia.| Alzheimer's News Today
BioXcel plans to test BXCL501 for treating agitation in Alzheimer’s disease dementia in patients in nursing and assisted living facilities.| Alzheimer's News Today
As columnist Ray Burow watched her mother's dementia progress, she often returned to a friend's wise words about coping with loss.| Alzheimer's News Today
Wallowing in self-pity is tempting in the wake of an Alzheimer's diagnosis, but it's crucial to keep moving forward, says columnist Ray Burow.| Alzheimer's News Today
A reader's comment prompts columnist Ray Burow to reinforce the purpose of her column: providing hope to those with an Alzheimer's diagnosis.| Alzheimer's News Today
A breast cancer diagnosis is particularly problematic — yet possible — for women caregivers, columnist Ray Burow writes.| Alzheimer's News Today
Columnist Ray Burow remembers her recently passed mother-in-law, who remained loving and loved during her short-term memory loss.| Alzheimer's News Today
Leqembi, Eisai and Biogen’s amyloid-targeted antibody therapy, has earned FDA approval for the treatment of Alzheimer’s disease.| Alzheimer's News Today
Biogen is discontinuing development and commercialization of its controversial Alzheimer's treatment Aduhelm to focus its efforts on Leqembi.| Alzheimer's News Today
One-year data from a Phase 2 trial's extension showed safe and rapid, sustained drops in beta-amyloid levels in early stage patients.| Alzheimer's News Today
Simufilam, a small molecule targeting the filamin A protein, is being tested in clinical trials to potentially treat Alzheimer's disease.| Alzheimer's News Today
Nearly half of some 200 mild-to-moderate Alzheimer’s patients treated with oral simufilam for one year showed gains in cognitive tests.| Alzheimer's News Today
Columnist Ray Burow now understands that those who get an Alzheimer's diagnosis need time to come to grips with the disease.| Alzheimer's News Today
Metabolic syndrome is associated with an increased risk of dementia among people with Parkinson's disease, according to a study from Turkey.| Parkinson's News Today
The findings support the idea that gut microbiota and the gut-brain axis factor in NMOSD, and that approaches like GV-971 may help patients.| Neuromyelitis News
Blocking the stress sensor GADD45G in astrocytes — star-shaped cells that support neurons — may be a therapeutic strategy for Parkinson’s.| Parkinson's News Today
The new ApoE4 Alzheimer's Alliance plans to advocate on behalf of patients with this gene variant for more supportive U.S. policies.| Alzheimer's News Today
Leqembi has been approved in the European Union for the treatment of certain adults with early Alzheimer's disease and mild cognitive issues.| Alzheimer's News Today
Blood levels of 2 proteins in REM sleep behavior disorder patients linked with later finding of Parkinson's-like disease, Lewy body dementia.| Parkinson's News Today
Early menopause and poor brain-connection health may interact to increase Alzheimer's disease risk in women, a study found.| Alzheimer's News Today
Winter in a cold climate can add challenges when caregiving for someone with dementia, columnist Ray Burow writes.| Alzheimer's News Today
The company recently announced results from two Phase 3 trials of AXS-05 for agitation. ACCORD-2, hit its main goal, but ADVANCE-2 didn't.| Alzheimer's News Today
Columnist Ray Burow, grieving the loss of her dear friend Richard Allen Farmer, reflects on how he cared for her mother, who had Alzheimer's.| Alzheimer's News Today
In a trial, once-daily buntanetap halted cognitive decline in early-stage Parkinson's and improved cognition in patients with mild dementia.| Parkinson's News Today
US neurologists are optimistic about the potential for a new Huntington's disease treatment - preferably a gene therapy - per a market survey.| Huntington's Disease News
Experts in Alzheimer’s and dementia care explain the challenges of getting an early and accurate diagnosis and what can be done to solve it.| Alzheimer's News Today
Early-onset Alzheimer's is a rare form of dementia that occurs between ages 30 and 60, and may affect several members of a single family.| Alzheimer's News Today
Columnist Ray Burow offers factors to consider when discussing whether nursing home care or at-home care is better for your loved one.| Alzheimer's News Today
A rare APOE gene mutation may protect against Alzheimer's by stopping the spread of toxic tau protein clumps in the brain, a study found.| Alzheimer's News Today
Buntanetap lowered amyloid-beta and tau levels in people with early Alzheimer's disease and its developer Annovis Bio is planning more trials.| Alzheimer's News Today
The FDA issued a letter encouraging the use of an alpha-synuclein assay to improve the efficiency of clinical trials in Parkinson's disease.| Parkinson's News Today
Understanding and identifying epigenetic changes in blood samples from people with Parkinson’s disease may help assess the risk of dementia.| Parkinson's News Today
The clinical trial is assessing the safety of Allyx Therapeutics' ALX-001 versus a placebo when given to adults twice daily for 28 days.| Parkinson's News Today
Recruitment has begun at the first clinical site of START, a Phase 2 study evaluating Elayta in adults with early Alzheimer's disease.| Alzheimer's News Today
CT1812 is an oral medication being developed by Cognition Therapeutics, now in clinical testing, to possibly treat mild-to-moderate Alzheimer’s disease by preventing the build up of beta-amyloid in the brain.| Alzheimer's News Today
Under-the-skin injections worked better in trial than the approved Leqembi formulation in clearing harmful amyloid plaques in Alzheimer's.| Alzheimer's News Today
Two proteins, neurofilament light chain and phosphorylated tau, can serve as markers of Huntington's disease progression, a study found.| Huntington's Disease News
Levels of GFAP in cerebrospinal fluid (CSF) may be a marker of Huntington’s disease progression, a study found.| Huntington's Disease News
Starting treatment with PrimeC six months sooner was associated with slower disease progression and a survival benefit for ALS patients.| ALS News Today
Tetra Therapeutics’ investigational oral therapy BPN14770 safely and effectively improved cognitive function in men with fragile X syndrome.| Fragile X News Today
The FDA has approved a Phase 2 trial to test SPG601, an oral treatment candidate, in men with fragile X syndrome.| Fragile X News Today
Anavex is preparing meetings with regulatory authorities in the U.S., Europe, and Asia-Pacific to discuss Anavex 2-73’s potential approval.| Alzheimer's News Today
Anavex 2-73 is an oral therapy, now in clinical testing, that activates the sigma-1 receptor to potentially modify the course of Alzheimer’s disease.| Alzheimer's News Today
Alpha Cognition’s ALPHA-1062 for Alzheimer’s showed efficacy in a trial as a bioequivalent substitute for the approved therapy Razadyne.| Alzheimer's News Today
Alpha Cognition’s oral tablet ALPHA-1062 may be a bioequivalent to galantamine hydrobromide – sold as Razadyne – for Alzheimer’s disease.| Alzheimer's News Today
The immunotherapy Leqembi, formerly BAN2401, is now FDA-approved for slowing cognitive decline in patients with Alzheimer's disease.| Alzheimer's News Today
Read a summary of the causes Alzheimer's disease, inclouding neurofibrillary tangles, inflammation, vascular and environmental factors, genetics and aging.| Alzheimer's News Today
Being a sole caregiver for a loved one with Alzheimer's is hard work, says columnist Ray Burow, but help and resources are available.| Alzheimer's News Today
Kisunla (donanemab-azbt) is an antibody-based therapy approved in the U.S. for adults with early symptomatic Alzheimer’s disease.| Alzheimer's News Today
Columnist Ray Burow explains how her mother's Alzheimer's called to mind Dickens' quote about the "spring of hope" and "winter of despair."| Alzheimer's News Today
Diagnosis of Alzheimer's disease involves assessing patients' medical history, symptoms, lab tests, and using brain imaging to rule out other conditions.| Alzheimer's News Today
Learn more about the symptoms of Alzheimer’s disease, the most common form of dementia, and its several stages. Alzheimer's symptoms may be different for each patient.| Alzheimer's News Today
Taking on caregiving for a loved one with Alzheimer's can seem impossible, says columnist Ray Burow, but only until it's done.| Alzheimer's News Today
There is great value in the relationship between grandparents and grandchildren, columnist Ray Burow says, even if Alzheimer's is involved.| Alzheimer's News Today
Treatment with Lomecel-B in early Alzheimer's patients led to improvements in cognitive tests relative to a placebo in a clinical trial.| Alzheimer's News Today
After her father passed away, columnist Ray Burow had to help her mother, who had Alzheimer's, process her emotions and grief.| Alzheimer's News Today
Experimental blarcamesine (Anavex 2-73) was able to slow cognitive and functional decline in early Alzheimer’s patients over a year, data show.| Alzheimer's News Today
Zunveyl, a new oral mild-to-moderate Alzheimer's therapy, showed bioequivalence to galanotamine but fewer GI issues like nausea in studies.| Alzheimer's News Today
Columnist Ray Burow, reflecting on caregiving for her late mother, ponders if it's sometimes OK to lie to a person with Alzheimer's disease.| Alzheimer's News Today
The use of Montelukast oral film was shown to improve cognition in patients with mild to moderate Alzheimer's in a Phase 2 clinical trial.| Alzheimer's News Today
The FDA granted regenerative medicine advanced therapy (RMAT) status to experimental cell therapy Lomecel-B for mild Alzheimer’s disease.| Alzheimer's News Today
Eli Lilly's donanemab, now Kisunla, was approved by the U.S. Food and Drug Administration for patients with early symptomatic Alzheimer’s.| Alzheimer's News Today
The safety and efficacy of buntanetap therapy are comparable in early Alzheimer’s patients regardless of APOE4 status, per new trial data.| Alzheimer's News Today
With the high temperatures expected this summer, columnist Ray Burow recalls tips she used to help loved ones with dementia handle the heat.| Alzheimer's News Today
The Phase 2 study will further assess SNK01's safety and its efficacy in about 30 patients who'll receive it every three weeks up to a year.| Alzheimer's News Today
An advisory committee to the U.S. Food and Drug Administration (FDA) unanimously voted in favor of donanemab for early Alzheimer's.| Alzheimer's News Today
Columnist Ray Burow can attest to the challenges that sandwich generation caregivers face, but says her children learned valuable lessons.| Alzheimer's News Today
Buntanetap, a small molecule from Annovis Bio, improved cognitive function in people with mild Alzheimer’s with certain biomarkers.| Alzheimer's News Today
Eisai has started a rolling application seeking U.S. FDA approval of an under-the-skin injection version of Leqembi for early Alzheimer’s.| Alzheimer's News Today
Eisai is seeking FDA approval of a monthly maintenance IV regimen of Leqembi for people with early Alzheimer’s disease.| Alzheimer's News Today
A total of 1,929 Alzheimer's patients have enrolled in two simufilam studies, which the FDA said could support its application for approval.| Alzheimer's News Today
Learn about Parkinson's disease, a condition that affects the brain, resulting in issues with movement, balance, and more.| Parkinson's News Today
